Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Nuedexta on Bulbar Physiology in ALS
NCT03883581Phase 2Completed
- Sponsor
- University of Florida
- Start
- Jul 2019
- Primary completion
- Sep 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dextromethorphan + quinidine in amyotrophic lateral sclerosis (ALS), sponsored by University of Florida. Primary endpoints: Change in Dynamic Imaging Grade of Swallowing Toxicity at Day 30, Change in Speech Intelligibility at Day 30 and 3 more. Started Jul 2019; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03883581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883581.